Primorigen Biosciences will accelerate work on its system for large scale production of stem cells thanks to more than $1.9 million in Phase II SBIR grants, the company announced recently.

“(The funding validates) both our business and technical directions,” Chuck Oehler, CEO of Primorigen, said in a statement. “We are excited about the opportunity to advance the industrialization of stem cells.”

According to Primorigen, its system is designed to address the emerging commercial need for stem cells in the clinical and drug discovery markets by reducing the number of steps and materials involved in their production.

The Madison, Wis.,-based company also received two Phase I SBIR grants in the past few months.